Links to NCI Materials
Links to Other Materials
Current Clinical Trials
Links to NCI Materials
Menopausal hormone use (sometimes referred to as hormone replacement therapy or HRT) usually involves treatment with either estrogen alone or a combination of estrogen with progesterone or progestin, a synthetic hormone with effects similar to those of progesterone.
The best evidence for the risks and benefits of menopausal hormone replacement therapy comes from the Women's Health Initiative (WHI), a large randomized clinical trial including more than 16,000 healthy women, sponsored by the National Institutes of Health (NIH).
Results from the trial published in 2002 showed that the overall risks of estrogen plus progestin outweigh the benefits. Among the risks observed after 5.6 years of follow-up were increased risks of breast cancer, heart disease, stroke and blood clots.
On March 1, 2004, after nearly seven years of follow-up, NIH stopped the estrogen-alone arm of the trial, concluding that estrogen alone does not appear to affect (either increase or decrease) heart disease, a key question of the study. In addition, estrogen alone appears to increase the risk of stroke and decrease the risk of hip fracture. No increase in breast cancer risk was observed during the study period.
Menopausal Hormone Replacement Therapy Use and Cancer: Questions and Answers
(Reviewed: 10/05/2007) - A fact sheet about the results of research on menopausal hormone replacement therapy use. Includes information about the effect of menopausal hormone replacement therapy use on the body. Also outlines the benefits and risks of using menopausal hormones. National Cancer Institute Fact Sheet 3.76
Menopausal Hormone Therapy and Ovarian Cancer: Questions and Answers
(Posted: 10/03/2006) - In a recent study published in the Journal of the National Cancer Institute, NCI and AARP reported that five or more years of estrogen plus progestin use significantly increased the risk of ovarian cancer for women who have not had a hysterectomy.
Hormone Replacement Therapy and Breast Cancer Relapse
(Posted: 02/05/2004, Reviewed: 04/08/2008) - Breast cancer survivors who took hormone replacement therapy (HRT) to relieve menopausal symptoms had more than three times as many breast cancer recurrences as survivors who did not take HRT, according to a Lancet report published online February 3, 2004.
Increased Risk of Ovarian Cancer Is Linked to Estrogen Replacement Therapy
(Posted: 07/16/2002) - Researchers from the NCI have found that women in a large study who used estrogen replacement therapy after menopause were at increased risk for ovarian cancer.
Experts Weigh in on Hormone Therapy
(Posted: 08/30/2002) - The stopping of a major hormone therapy trial in early July 2002 has sent many women to their health care providers for advice on whether to continue hormone use.
Uso de hormonas después de la menopausia: preguntas y respuestas
(Publicación: 07/09/2002) - La menopausia es la transición entre los años en los que una mujer puede embarazarse y los años en los que el embarazo ya no es posible.
Back to Top
Links to Other Materials
Menopausal Hormone Therapy Information from NIH
The links on this page point to information resources, including the most current from the National Institutes of Health (NIH), on both long-term and short-term hormone use, and other concerns related to women's health during and after menopause.
NIH Asks Participants in Women's Health Initiative Estrogen-Alone Study to Stop Study Pills, Begin Follow-up Phase
A March 2, 2004 announcement from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to have WHI participants in the estrogen-alone arm of the study stop taking study medications and enter the follow-up phase.
Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women
Following a review of data from the Women's Health Initiative study, the Food and Drug Administration (FDA) on Jan. 8, 2003, began advising women and health care professionals about important new safety changes to labeling of all estrogen and estrogen with progestin products for use by postmenopausal women.
NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit
A July 9, 2002, announcement from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health concerning the decision to stop early a major clinical trial of the risks and benefits of combined estrogen and protestin in healthy menopausal women due to an increased risk of invasive breast cancer.
The Women's Health Initiative (WHI)
A page of information about the WHI maintained by the National Heart, Lung, and Blood Institute (NHLBI), the initiative's lead sponsor.
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women
Principal results from the Women's Health Initiative randomized controlled trial, as published in the July 17, 2002, issue of the Journal of the American Medical Association (JAMA).
U.S. Preventive Services Task Force & HRT
To determine the current status of benefits and harms of hormone replacement therapy (HRT) use, systematic searches of the literature on HRT were conducted for the U.S. Preventive Services Task Force.
Back to Top
Current Clinical Trials
Early Detection and Prevention Trials for Breast Cancer
From NCI's clinical trials database.
Early Detection and Prevention Trials for Colorectal Cancer
From NCI's clinical trials database.
Back to Top
|
